Dr Moskowitz said: “This rapid mobilization of major medical centers across the United States reflects
the urgent need to treat the very large numbers of people in hospital intensive care units suffering
with COVID-19 ARDS and requiring ventilation. We expect quick enrollment in this trial to determine
whether remestemcel-L can reduce mortality in these patients.”
Ann: First Patients Dosed in Phase 2/3 Trial for COVID-19 ARDS, page-3
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
0.000(0.00%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.08 | $5.380M | 4.893M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 69437 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 19999 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |